A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00807677
First received: December 10, 2008
Last updated: July 1, 2013
Last verified: July 2013
  Purpose

The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.


Condition Intervention Phase
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Waldenstrom's Macroglobulinemia
Myelodysplastic Syndrome
Philadelphia Chromosome-negative CML
Myeloid Metaplasia
Myelofibrosis
Advanced Polycythemia
Non-Hodgkins Lymphoma
Drug: TAK-901
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Resource links provided by NLM:


Further study details as provided by Millennium Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To determine the maximum tolerated dose(MTD)of TAK-901 in subjects with advanced hematologic malignancies. [ Time Frame: Duration of the study ] [ Designated as safety issue: Yes ]
  • To further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies. [ Time Frame: Duration of study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the pharmacokinetic profile of TAK-901 and its primary metabolite (M-I). [ Time Frame: Duration of the study ] [ Designated as safety issue: Yes ]
  • To make a preliminary assessment of the clinical activity of TAK-901. [ Time Frame: Duration of therapy ] [ Designated as safety issue: No ]
  • To make a preliminary assessment of the effects of TAK-901 on pharmacodynamic biomarkers. [ Time Frame: Duration of therapy ] [ Designated as safety issue: No ]
  • To make a preliminary assessment of the association between selected genetic markers and TAK-901 response and/or pharmacokinetic parameters. [ Time Frame: Duration of therapy ] [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: March 2009
Study Completion Date: March 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
TAK-901
Drug: TAK-901
TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. The subject has one of the following confirmed diseases that is refractory to or relapsed from established therapies. Note: A subject with one of these disease who is intolerant (as defined in the protocol) to established therapies is also allowed:

    1. Acute myelogenous leukemia
    2. Acute lymphoblastic leukemia
    3. Chronic myelogenous leukemia (CML) (chronic phase, accelerated phase, or blast crisis)
    4. Chronic lymphocytic leukemia
    5. Multiple myeloma
    6. Waldenstrom's macroglobulinemia
    7. Intermediate or high risk myelodysplastic syndrome
    8. One of the following myeloproliferative disorders:

      • Philadelphia chromosome-negative CML (including blast phase).
      • All subtypes of myeloid metaplasia with myelofibrosis.
      • Advanced polycythemia vera in the spent phase (ie, presence of anemia).
    9. Non-Hodgkins lymphoma
  2. The interval between the last prior treatment and the start of study drug administration is at least 30 days for radiotherapy, at least 14 days for cytotoxic chemotherapy (42 days for nitrosureas or mitomycin C), and at least 5 half-lives for noncytotoxic agents. The only exception is hydroxyurea, which can be used prior to starting study drug and during Cycle 1, as defined in the protocol.
  3. For subjects with prior autologous bone marrow or peripheral blood stem cell transplantation, the interval between transplant and the start of study drug administration is at least 30 days.
  4. For subjects with prior allogeneic bone marrow or peripheral blood stem cell transplantation, the interval between transplant and the start of study drug administration is at least 90 days.
  5. If taking steroids chronically, the subject has been receiving a stable steroid dose for at least 21 days prior to the start of study drug administration, and the daily steroid dose does not exceed the equivalent of 20 mg prednisone.
  6. The subject is aged 18 years or older.
  7. The subject weighs at least 45 kg.
  8. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  9. The subject has adequate liver and kidney function.
  10. The subject has adequate heart function (left ventricular ejection fraction ≥ 50%).

Main Exclusion Criteria:

Any subject who meets any of the following criteria will not qualify for entry into the study:

  1. The subject has a platelet count (untransfused) < 50,000/mm3 and/or an absolute neutrophil count < 1000/mm3 that is not caused by the underlying disease infiltrating the bone marrow.
  2. The subject has evidence of active malignancy in the central nervous system (CNS)or has had CNS involvement documented within the past 90 days. Subjects who are receiving maintenance intrathecal chemotherapy for previous CNS involvement but have no current evidence of disease are allowed if the CNS involvement was documented more than 90 days ago.
  3. The subject has any evidence of acute or chronic graft versus host disease.
  4. The subject has a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical composition to TAK-901 or its excipient, Captisol.
  5. The subject is pregnant or lactating.
  6. The subject has had a myocardial infarction, cerebrovascular accident, transient ischemic attack, clinically significant ventricular arrhythmia, or pulmonary embolus within 6 months prior to the start of study drug administration.
  7. The subject's electrocardiogram demonstrates an abnormal QT interval , as defined by the protocol.
  8. The subject requires dialysis.
  9. The subject is on systemic anticoagulation therapy.
  10. The subject has an uncontrolled intercurrent illness as defined in the protocol.
  11. The subject is known to have human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
  12. The subject has a currently active second malignancy other than nonmelanoma skin cancer or in situ carcinoma of the cervix. A malignancy is considered to be currently active if the subject is receiving ongoing therapy or has been in remission for less than 2 years prior to the first dose of study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00807677

Locations
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Investigators
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00807677     History of Changes
Other Study ID Numbers: TAK-901_101
Study First Received: December 10, 2008
Last Updated: July 1, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Millennium Pharmaceuticals, Inc.:
Chronic myelogenous leukemia (CML) in chronic phase, accelerated phase, or blast crisis
Intermediate or high risk myelodysplastic syndrome
Philadelphia chromosome-negative CML (including blast phase)
All subtypes of myeloid metaplasia with myelofibrosis; advanced polycythemia

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Multiple Myeloma
Neoplasms, Plasma Cell
Myelodysplastic Syndromes
Preleukemia
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Waldenstrom Macroglobulinemia
Polycythemia
Philadelphia Chromosome
Metaplasia
Leukemia
Syndrome
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias

ClinicalTrials.gov processed this record on September 22, 2014